Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ramipril
Drug ID BADD_D01909
Description Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril may be used in the treatment of hypertension, congestive heart failure, nephropathy, and to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events.
Indications and Usage For the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. [FDA Label] To reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. May be used to slow the progression of renal disease in individuals with hypertension, diabetes mellitus and microalubinuria or overt nephropathy. [T116]
Marketing Status approved
ATC Code C09AA05
DrugBank ID DB00178
KEGG ID D00421
MeSH ID D017257
PubChem ID 5362129
TTD Drug ID D01STB
NDC Product Code 76282-671; 53104-7573; 50090-5730; 50090-5947; 57237-225; 62135-273; 63629-1254; 65841-701; 65862-475; 68180-590; 70518-3038; 71205-029; 65862-476; 57237-222; 60760-476; 61570-111; 62135-274; 68001-429; 0054-0108; 71335-1057; 51655-904; 63187-277; 65841-656; 65841-657; 65841-700; 65841-702; 62135-271; 63187-073; 65841-699; 65862-477; 0054-0106; 68382-145; 68382-147; 68382-376; 71335-0894; 71335-1056; 76282-672; 55111-057; 16729-152; 50090-4691; 51655-296; 61570-110; 63187-816; 68382-146; 82348-101; 16729-153; 45865-441; 51655-347; 51655-406; 61570-112; 63187-644; 65841-655; 65841-658; 68180-589; 68382-144; 70518-1200; 76282-670; 17404-1021; 16729-154; 50090-5673; 60760-571; 63187-854; 63187-915; 0054-0109; 68382-375; 65862-320; 65862-474; 68554-0004; 51655-346; 60760-481; 62135-272; 68001-428; 0054-0107; 68180-591; 71205-080; 58032-0123; 16729-155; 45865-443; 51655-975; 68001-430; 68001-431; 71335-9645; 76282-673; 69037-0051; 61570-120; 68382-374; 68382-377; 15308-0300; 57237-223; 57237-224
UNII L35JN3I7SJ
Synonyms Ramipril | Vesdil | Triatec | Altace | Zabien | Ramace | Tritace | Acovil | Delix | Carasel | HOE-498 | HOE 498 | HOE498
Chemical Information
Molecular Formula C23H32N2O5
CAS Registry Number 87333-19-5
SMILES CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C3CCCC3CC2C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Shock24.06.02.0020.000746%Not Available
Sinus bradycardia02.03.03.0090.000093%
Sinus tachycardia02.03.03.0100.000326%
Sinusitis22.07.03.007; 11.01.13.005--
Skin discolouration23.03.03.0050.000233%Not Available
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.0030.000373%Not Available
Skin irritation23.03.04.0090.000317%Not Available
Skin necrosis23.03.03.0110.000140%Not Available
Skin reaction23.03.03.013; 10.01.03.0190.000093%Not Available
Sleep disorder19.02.04.0010.000746%Not Available
Sluggishness08.01.01.0040.000326%Not Available
Small intestinal obstruction07.13.06.0010.000233%
Social avoidant behaviour19.05.01.0070.000186%Not Available
Somnolence19.02.05.003; 17.02.04.006--
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.0030.000466%Not Available
Spinal osteoarthritis15.01.04.0030.000093%Not Available
Sputum increased22.02.03.0070.000093%Not Available
Squamous cell carcinoma16.16.01.0020.000280%Not Available
Squamous cell carcinoma of skin23.08.02.005; 16.03.02.0050.000093%Not Available
Stevens-Johnson syndrome10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.005--
Stillbirth18.01.02.002; 08.04.01.0060.000373%Not Available
Stomatitis07.05.06.005--
Stress19.06.02.004--Not Available
Stridor22.04.02.0030.000093%
Subarachnoid haemorrhage24.07.04.004; 17.08.01.010; 12.01.10.0110.000233%Not Available
Suicide attempt19.12.01.0040.001026%
Swelling08.01.03.0150.002135%Not Available
Swelling face08.01.03.100; 23.04.01.018; 10.01.05.0180.001408%Not Available
Swollen tongue23.04.01.014; 10.01.05.015; 07.14.02.0030.003851%Not Available
The 15th Page    First    Pre   15 16 17 18 19    Next   Last    Total 23 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene